Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Yellow Fever

Yellow Fever

Part of Flavivirus Infections

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Yellow Fever

7 trials tracked for Yellow Fever: 2 in phase 3 or 4.

7Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 3 Phase 1 2
  1. Phase 3 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed
  2. Phase 3 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed
  3. Phase 2 Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed
  4. Phase 2 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination Completed
  5. Phase 2 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed
  6. Phase 1 Trial of Yellow Fever Inactivated Vaccine Completed
Show 1 more trials
  1. Phase 1 Trial of an Inactivated Yellow Fever Virus Vaccine Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
One-fifth and one-half doses of 17DD yellow fever vaccine meet non-inferiority for seroconversion
Pediatrics RCT
One-fifth and one-half doses of 17DD yellow fever vaccine meet non-inferiority for seroconversion Smaller doses of yellow fever vaccine may still protect children
This randomized clinical trial of 1784 children aged 9-23 months in Uganda found that both one-fifth and one-half doses of the 17DD yellow f…
A trial in Uganda shows that smaller doses of the yellow fever vaccine can provide the same protection as a full dose.
Oct 17, 2026
Yellow fever booster in Gambian children yields strong antibody rise
Drug Pipeline Phase III
Yellow fever booster in Gambian children yields strong antibody rise Booster dose increases yellow fever protection in young children
A 17D booster in 610 Gambian children produced 99% seropositivity and antibody rises up to 7.7-fold, with no vaccine-related serious events.
A booster shot significantly increased protective antibodies against yellow fever in children aged 1 to 9 in a Gambian health center study.
Oct 12, 2026
Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review
Infectious Disease Sys. Review
Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review Review Outlines Treatment and Prevention for Various Viral Infections
This systematic review covers the molecular biology, epidemiology, and treatment strategies for various viral infections including Hepatitis…
A comprehensive review outlines the biological traits, diagnosis methods, and treatment strategies for several common viral infections inclu…
Frontiers Sep 19, 2026
Environmental and social factors influence arbovirus proliferation in changing climate conditions
Infectious Disease Cohort
Environmental and social factors influence arbovirus proliferation in changing climate conditions Rising Temperatures Push Dangerous Viruses Into New Communities
This review examines how environmental and social factors, including increasing temperatures and urbanization, affect the proliferation of a…
Warming weather pushes dangerous insect-borne viruses into new areas, making early warning systems and vaccines more critical than ever for …
Frontiers Apr 28, 2026
Meta-analysis finds 30.7% molecular prevalence of yellow fever virus in non-human primates
Infectious Disease Meta-analysis
Meta-analysis finds 30.7% molecular prevalence of yellow fever virus in non-human primates Yellow fever virus found in many monkeys in the Americas, study shows
A meta-analysis of 39 studies involving 7,183 non-human primates found pooled molecular prevalence of yellow fever virus infection was 30.7%…
Yellow fever virus was found in 31% of monkey samples and 43% of tissue tests, with infected animals in detailed cases all dying from severe…
Frontiers Apr 2, 2026

Questions about Yellow Fever

Is there a specific antiviral drug for Yellow Fever?

There are currently no specific drugs approved for the treatment of yellow fever, though research into antiviral therapies and entry inhibitors is ongoing.

Full answer →